Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sar-125844. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800301 | 0.93 | MET (1.00) | METCYP3A4 | |
| SCHEMBL2801567 | 0.92 | MET (0.86) | METCYP3A4 | |
| SCHEMBL3795365 | 0.91 | MET (0.83) | METCYP3A4 | |
| SCHEMBL2763173 | 0.89 | MET (1.00) | METCYP3A4 | |
| SCHEMBL2764009 | 0.89 | MET (1.00) | METCYP3A4 | |
| SCHEMBL2868610 | 0.89 | MET (0.79) | METCYP3A4 | |
| SCHEMBL3806681 | 0.89 | MET (0.89) | METCYP3A4 | |
| SCHEMBL2799218 | 0.87 | MET (0.77) | METCYP3A4 | |
| SCHEMBL2801184 | 0.87 | MET (0.80) | METCYP3A4 | |
| SCHEMBL15282283 | 0.87 | MET (0.77) | METCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601644-A1 | METHODS OF TREATING CANCERS USING ISOQUINOLINE OR 6-AZA-QUINOLINE DERIVATIVES | Black Diamond Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | claimed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | claimed |
| WO-2024081916-A1 | METHODS OF TREATING CANCERS USING ISOQUINOLINE OR 6-AZA-QUINOLINE DERIVATIVES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| CN-117835978-A | Pharmaceutical combinations comprising TEAD inhibitors and their use for cancer treatment | 诺华股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| CN-117159715-A | New use of inhibitor and inhibitor screening model | 中国农业大学 | 2023-12-05 | — | — | CN | claimed |
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| US-9115134-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2015-08-25 | — | — | US | claimed |
| EP-2872119-A1 | ANTI-TUMORAL COMPOSITION COMPRISING THE COMPOUND 1-(6-{[6-(4-FLUOROPHENYL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]SULFANYL}-1,3-BENZOTHIAZOL-2-YL)-3-(2-MORPHOLIN-4-YLETHYL)UREA | SANOFI (FR) | 2015-05-20 | — | — | EP | claimed |
| US-20150119391-A1 | ANTI-TUMORAL COMPOSITION COMPRISING THE COMPOUND 1-(6--1,3-BENZOTHIAZOL-2-YL)-3-(2-MORPHOLIN-4-YLETHYL)UREA | SANOFI (FR) | 2015-04-30 | — | — | US | claimed |
| WO-2014009500-A1 | ANTI-TUMORAL COMPOSITION COMPRISING THE COMPOUND 1-(6-{[6-(4-FLUOROPHENYL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]SULFANYL}-1,3-BENZOTHIAZOL-2-YL)-3-(2-MORPHOLIN-4-YLETHYL)UREA | SANOFI (FR) | 2014-01-16 | — | — | WO | claimed |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI (FR) | 2014-01-02 | — | — | US | claimed |
| EP-2178881-B1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | claimed |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2009056692-A2 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | TP53, TEAD2, SERPINB1 | MET 432/4885CYP3A4 1743/4885 |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | MET 1/4885CYP3A4 224/4885 |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | BMX, MET, TPMT | MET 2/4885CYP3A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.